Abstract:The clinical symptoms of pancreatic cancer are not obvious, and most patients have developed to the middle and late stage after discovery, which is due to the lack of reliable biomarkers and the limited resolution of retroperitoneal imaging technology. Therefore, finding biomarkers for early diagnosis and early detection of pancreatic cancer has become the top priority of clinical research. Exosomes exist in body fluids and encapsulate DNA, RNA, proteins, and metabolites derived from secreted tissues. The detection of exosome in body fluids can reveal information about their source tissues, and has broad application prospects in in vitro diagnosis. This study reviews the clinical value of miRNA detection and combined detection in the early diagnosis of pancreatic cancer.